Prescription of second-generation antipsychotics: Responding to treatment risk in real-world practice

Psychiatric Services

Volumn 64, Issue 3, 2013, Pages 238-244

  Hermes, Eric D A ^a   Sernyak, Michael J ^a,b   Rosenheck, Robert A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEALTH CARE PRACTICE; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OBESITY; PRESCRIPTION; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

AGED; ANTIPSYCHOTIC AGENTS; CHOICE BEHAVIOR; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; UNITED STATES;

EID: 84883056679     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201200183     Document Type: Article

References (37)

1. Verdoux H, Tournier M, Bégaud B: Antipsychotic prescribing trends: A review of pharmaco-epidemiological studies. Acta Psychiatrica Scandinavica 121:4-10, 2010
2. Davis JM, Chen N, Glick ID: A metaanalysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60:553-564, 2003
3. Leucht S, Wahlbeck K, Hamann J, et al: New generation antipsychotics versus lowpotency conventional antipsychotics: A systematic review and meta-analysis. Lancet 361:1581-1589, 2003
4. Leslie DL, Mohamed S, Rosenheck RA: Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatric Services 60: 1175-1181, 2009
5. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353: 1209-1223, 2005
6. Miller DD, Caroff SN, Davis SM, et al: Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journal of Psychiatry 193:279-288, 2008
7. Jones PB, Barnes TR, Davies L, et al: Randomized controlled trial of the effect on quality of life of second-vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63:1079-1087, 2006
8. Rosenheck R, Perlick D, Bingham S, et al: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial. JAMA 290:2693-2702, 2003
9. Blin O, Micallef J: Antipsychotic-associated weight gain and clinical outcome parameters. Journal of Clinical Psychiatry 62(suppl 7):11-21, 2001
10. Allison DB, Mentore JL, Heo M, et al: Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 156:1686-1696, 1999
11. Henderson DC, Cagliero E, Gray C, et al: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. American Journal of Psychiatry 157:975-981, 2000
12. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19(suppl 1):1-93, 2005
13. Csernansky JG, Mahmoud R, Brenner R: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 346:16-22, 2002
14. Brecher M, Leong RW, Stening G, et al: Quetiapine and long-term weight change: A comprehensive data review of patients with schizophrenia. Journal of Clinical Psychiatry 68:597-603, 2007
15. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists, et al: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Obesity Research 12:362-368, 2004
16. Marder SR, Essock SM, Miller AL, et al: Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161:1334-1349, 2004
17. Greenberg G, Rosenheck R: Department of Veterans Affairs National Mental Health Program Performance Monitoring System: Fiscal Year 2007 Report. West Haven, Conn, Northeast Program Evaluation Center, 2008
18. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
19. Das SR, Kinsinger LS, Yancy WS, Jr, et al: Obesity prevalence among veterans at Veterans Affairs medical facilities. American Journal of Preventive Medicine 28: 291-294, 2005
20. Dassori AM, Copeland LA, Zeber JE, et al: Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia. Psychiatric Services 62:47-53, 2011
21. Kilbourne AM, Brar JS, Drayer RA, et al: Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics 48:412-417, 2007
22. Neugaard BI, Priest JL, Burch SP, et al: Quality of care for veterans with chronic diseases: performance on quality indicators, medication use and adherence, and health care utilization. Population Health Management 14:99-106, 2011
23. Yu W, Ravelo A, Wagner TH, et al: Prevalence and costs of chronic conditions in the VA health care system. Medical Care Research and Review 60(suppl):146S-167S, 2003
24. Wetterling T: Bodyweight gain with atypical antipsychotics: A comparative review. Drug Safety 24:59-73, 2001
25. Daumit GL, Goff DC, Meyer JM, et al: Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research 105:175-187, 2008
26. Larsen JT, Fagerquist M, Holdrup M, et al: Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden. Nordic Journal of Psychiatry 65:40-46, 2011
27. Okumura Y, Ito H, Kobayashi M, et al: Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: A nationwide retrospective cohort study. Schizophrenia Research 119: 145-152, 2010
28. Sernyak MJ, Rosenheck RA: Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatric Services 59: 567-569, 2008
29. Hamann J, Kolbe G, Cohen R, et al: How do psychiatrists choose among different antipsychotics? European Journal of Clinical Pharmacology 61:851-854, 2005
30. Newcomer JW, Nasrallah HA, Loebel AD: The atypical antipsychotic therapy and metabolic issues national survey. Journal of Clinical Psychopharmacology 24(suppl 1): S1-S6, 2004
31. Dixon L, Perkins D, Calmes C: Practice guideline for the treatment of patients with schizophrenia, 2nd ed. American Journal of Psychiatry 161(suppl 2):1-56, 2004
32. Sadock BJ, Sadock VA, Ruiz P (eds): Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 9th ed. Philadelphia, Lippincott Williams and Wilkins, 2009
33. Hales RE, Yudofsky SC, Gabbard GO (eds): Textbook of Psychiatry, 5th ed. Arlington, Va, American Psychiatric Publishing, 2008
34. Goff DC, Sullivan LM, McEvoy JP, et al: A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research 80:45-53, 2005
35. Komossa K, Rummel-Kluge C, Schmid F, et al: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 4: CD006569, 2009
36. Kumra S, Kranzler H, Gerbino-Rosen G, et al: Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison. Biological Psychiatry 63:524-529, 2008
37. Beuzen JN, Avnon M, Belmaker RH, et al: The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clinical Therapeutics 22:1021-1034, 2000